Protagonist Therapeutics Inc (NASDAQ:PTGX) traded at $55.95 at close of the session on Monday, March 10 and made an upward move of 45.89% on its previous day’s price.
Protagonist Therapeutics Inc has a market cap of $3.43 billion and is expected to release its quarterly earnings report in April.
The median projection represents growth adding up to -88.06% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 98.78M, or -77.26% down from figures reported last year.
On the other hand, looking at the outlook for the PTGX stock, short term indicators assign the stock an average of Hold, while medium term indicators assign it an average of 50% Sell.
Based on estimates by 4 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Protagonist Therapeutics Inc (PTGX) stock as a Hold, while 4 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 44.69% off its SMA20 and 46.11% from its 50-day simple moving average. The RSI (14) is pointing at 83.01 while the volatility over the past week is 7.87% and jumps to 5.74% over the past one month. The beta value is 2.48, while the average true range (ATR) is currently pointing at 3.17. The average price target for the stock over the next 12 months is $61, with the estimates having a low of $50 and a high of $73. These price ends are 10.63% and -30.47% off the current price level respectively, although investors could be excited at the prospect of a -9.03% if the PTGX share price touches on the median price of $61.
